Yes, ARA290 (Cibinetide) Has Been Studied in Multiple Published Human Trials
ARA290 has been evaluated in at least three randomized, placebo-controlled, double-blind human studies, primarily in patients with sarcoidosis-associated small fiber neuropathy (SFN), plus additional trials in type 2 diabetes with neuropathy. 1
Published Human Studies Overview
Sarcoidosis-Associated Small Fiber Neuropathy Studies
The most robust evidence comes from three randomized, placebo-controlled, double-blind trials in sarcoidosis patients with SFN 1:
Initial pilot study (2012): 22 patients received either ARA290 (2 mg) or placebo via intravenous administration three times weekly for 4 weeks. Results showed significant improvement in the Small Fiber Neuropathy Screening List (SFNSL) score (Δ -11.5 vs Δ -2.9 for placebo, p<0.05), plus improvements in SF-36 pain and physical functioning dimensions 2
Follow-up trial (2013): 28 days of daily subcutaneous ARA290 administration demonstrated significant improvement in neuropathic symptoms, increased corneal nerve fiber density, changes in cutaneous temperature sensitivity, and improved 6-minute walk test performance 3
Third confirmatory study: Validated the consistent pattern of symptom reduction and corneal nerve fiber health improvements over short time-frames 1
Notably, the neuropathic benefits correlated with increases in the 6-minute walk distance, demonstrating important functional consequences beyond just symptom relief 1
Type 2 Diabetes with Neuropathy Study
A phase 2 study evaluated ARA290 (4 mg) administered subcutaneously daily for 28 days in patients with type 2 diabetes and painful neuropathy 4:
- Improved hemoglobin A1c (HbA1c) and lipid profiles throughout the 56-day observation period
- Significant improvement in neuropathic symptoms assessed by PainDetect questionnaire
- Increased corneal nerve fiber density in subjects with baseline deficits
Neuropsychological Study in Healthy Volunteers
One study (2015) tested ARA290 (2 mg) in 36 healthy participants using a neuropsychological model to assess potential antidepressant properties, though results did not clearly support an antidepressant profile 5
Clinical Significance and Current Status
According to the 2021 European Respiratory Society guidelines, cibinetide (ARA290) is "the most extensively studied and best-validated treatment to date for sarcoidosis-associated SFN" 1. However, critical limitations exist:
- Not FDA-approved for any indication 1
- Not currently commercially available 1
- Therefore, no formal clinical recommendations can be made despite promising evidence 1
Safety Profile
Across all human studies, no significant safety concerns were identified 4, 2. The peptide demonstrated an excellent safety profile without the hematopoietic side effects associated with erythropoietin, from which it was derived 6, 3.
Mechanism of Action
ARA290 functions as an innate repair receptor agonist with anti-inflammatory and neuroprotective properties 1. It selectively activates the innate repair receptor without stimulating erythropoiesis, distinguishing it from erythropoietin 4, 6, 3.